Sharad Ghamande, MD
Vaccine therapy is useful in both the prevention and treatment of cervical cancer, explains Sharad Ghamande, MD, and phase II findings of such treatment have demonstrated a survival benefit in a pretreated population.
, Ghamande, associate professor, Georgia Cancer Center, Augusta University, discussed the findings from GOG/NRG-0265, as well as the impact of vaccines for patients with cervical cancer.
OncLive: What was the rationale of the phase II GOG/NRG-0265 study for patients with cervical cancer?
: In the United States, there are 13,000 newly diagnosed cases of cervical cancer every year and about 4000 patients die. However, worldwide, there are almost 400,000 new cases of cervical cancer diagnosed every year. Unfortunately, almost 80% of patients present with advanced disease. In any given year, there are 250,000 women who die of cervical cancer.
... to read the full story